Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability

doi:10.3748/wjg.v26.i36.5437

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 36

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8597)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

474

WORD

120

HTML

3464

Figures (1-3)

506

Tables (1-4)

263

Sum=4827

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

455

Download

873

Sum=1328

Publishing Process of This Article

Item

Count

Browse

727

Download

1715

Sum=2442

Sep 28, 2020 (publication date) through Oct 3, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Sep 28, 2020; 26(36): 5437-5449
Published online Sep 28, 2020. doi: 10.3748/wjg.v26.i36.5437

Full Size Figure Download Figure

Figure 2 Needle-to-departure times for standard vs rapid (further subdivided by infusion centre and home based) infliximab protocols.

Citation: Bohra A, Rizvi QAA, Keung CYY, Vasudevan A, van Langenberg DR. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability. World J Gastroenterol 2020; 26(36): 5437-5449
URL: https://www.wjgnet.com/1007-9327/full/v26/i36/5437.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i36.5437